AstraZeneca

(IN BRIEF) AstraZeneca’s new drug application (NDA) for capivasertib, in combination with Faslodex, has been accepted and granted Priority Review by the US FDA for the treatment of advanced breast cancer. The NDA is being reviewed under Project Orbis, which … Read the full press release →

(IN BRIEF) AstraZeneca and Quell Therapeutics have announced a collaboration to develop innovative treatments for Type 1 Diabetes and Inflammatory Bowel Disease. Quell’s T-regulatory cell engineering technology will be used to create potential curative therapies. AstraZeneca has the option to … Read the full press release →

(IN BRIEF) AstraZeneca is set to present data on its Vaccines and Immune Therapies portfolio at the European Congress of Clinical Microbiology & Infectious Diseases. Among the data to be presented will be details on the progress of AstraZeneca’s Vaccines … Read the full press release →

(IN BRIEF) AstraZeneca will showcase new data from its industry-leading Oncology pipeline and portfolio at the American Association for Cancer Research Annual Meeting. A total of 70 presentations will be given, including a plenary presentation on the AEGEAN Phase III … Read the full press release →

(IN BRIEF) The Food and Drugs Authority of Ghana has granted full national licensure for the R21/Matrix-M malaria vaccine developed by the University of Oxford and manufactured by the Serum Institute of India using Novavax’s adjuvant technology. This marks the … Read the full press release →

(IN BRIEF) Sanofi has simplified its contractual arrangements with AstraZeneca and Sobi for the development and commercialization of Beyfortus (nirsevimab) in the United States. Under the new arrangements, Sanofi will have full commercial control of nirsevimab in the U.S. Sanofi … Read the full press release →

(IN BRIEF) A study published in the European Heart Journal – Open has found that excessive salt intake is associated with clogged arteries of the heart and neck, which is linked with increased risks of heart attack and stroke. Atherosclerosis, … Read the full press release →

(ACTUALITÉ EN BREF) The Co-operative Group Limited a annoncé qu’Adrian Marsh rejoindrait la société en tant qu’administrateur non exécutif indépendant et président du comité des risques et d’audit. Marsh prend sa retraite de son poste de directeur financier du groupe … Read the full press release →

(IN BRIEF) The Co-operative Group Limited has announced that Adrian Marsh will join the company as an Independent Non-Executive Director and Chair of the Risk and Audit Committee. Marsh is retiring from his role as Group Finance Director at FTSE … Read the full press release →

(ACTUALITÉ EN BREF) AstraZeneca a lancé le Défi postdoctoral R&D 2023, qui invite les étudiants en dernière année de médecine et/ou de doctorat et les chercheurs postdoctoraux du monde entier à soumettre leurs propres propositions de recherche. L’initiative est conçue … Read the full press release →

(IN BRIEF) AstraZeneca has launched the 2023 R&D Postdoctoral Challenge, which invites final-year MD and/or PhD students and postdoctoral researchers from around the world to submit their own research proposals. The initiative is designed to promote diversity of thought and … Read the full press release →

(PRESS RELEASE) CAMBRIDGE, 16-Jan-2023 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced the completion of its acquisition of Neogene Therapeutics Inc. Neogene is a global clinical-stage biotechnology company that specializes in the discovery, … Read the full press release →

(COMUNICADO DE PRENSA) CAMBRIDGE, 16-Jan-2023 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), una multinacional británica-sueca farmacéutica y de biotecnología, ha anunciado la finalización de su adquisición de Neogene Therapeutics Inc. Neogene es una compañía global de biotecnología en etapa clínica que … Read the full press release →

(PRESS RELEASE) CAMBRIDGE, 13-Jan-2023 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced that its drug Tezspire (tezepelumab) has been given the green light for self-administration by the European Medicine Agency’s Committee for Medicinal … Read the full press release →

(COMUNICADO DE PRENSA) CAMBRIDGE, 13-Jan-2023 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), una multinacional británica-sueco-farmacéutica y biotecnológica, ha anunciado que su fármaco Tezspire (tezepelumab) ha recibido luz verde para la autoadministración por parte del Comité de Medicamentos de Uso Humano (CHMP) … Read the full press release →